Inhibrx Announces Participation in Upcoming Investor Conference

Rhea-AI Summary

Inhibrx, Inc. (Nasdaq: INBX) announced its participation in the Guggenheim Healthcare Talks: 2021 Oncology Days, scheduled for February 12, 2021, at 2 p.m. Pacific Time. The presentation will be webcast live, accessible via the investor section of the Inhibrx website, and available for 60 days post-event. Inhibrx is focused on developing a pipeline of novel biologic therapies for oncology and orphan diseases, utilizing its proprietary sdAb platform and collaborating with companies like bluebird bio and Bristol-Myers Squibb.

News Market Reaction – INBX

+11.64%

+11.64% Session move

In the trading session that priced this news, INBX gained 11.64%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Feb. 1, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today that the Company will be presenting at the following upcoming virtual investor conference:

• Guggenheim Healthcare Talks: 2021 Oncology Days; Friday, February 12th, at 2 p.m. Pacific Time

The investor conference presentation will be webcast live and may be accessed through a link on the investors section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations. The webcast will be available for 60 days following the event.

About Inhibrx, Inc.

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi. For more information, please visit www.inhibrx.com.

Investor and Media Contact:

Amy Conrad
Juniper Point
amy@juniper-point.com
858-366-3243

View original content:http://www.prnewswire.com/news-releases/inhibrx-announces-participation-in-upcoming-investor-conference-301219478.html

SOURCE Inhibrx, Inc.

FAQ

When will Inhibrx present at the Guggenheim Healthcare Talks?

Inhibrx will present at the Guggenheim Healthcare Talks on February 12, 2021, at 2 p.m. Pacific Time.

How can I access the Inhibrx investor conference presentation?

The presentation can be accessed live via a link on Inhibrx's investor website and will be available for 60 days after the event.

What is the focus of Inhibrx's pipeline?

Inhibrx is focused on developing novel biologic therapeutic candidates for oncology and orphan diseases.

What collaborations does Inhibrx have?

Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb, and Chiesi.

What is the ticker symbol for Inhibrx?

The ticker symbol for Inhibrx is INBX.